COVID-19 Aşıları Hakkında Kapsamlı Bir İnceleme: Geliştirme, Etkinlik, Güvenlik ve Bağışıklık

Öz

Anahtar Kelimeler

• COVID-19 Aşıları
• COVID-19 Güçlendirici Aşılar
• Pfizer-BioNTech
• Moderna
• Bivalent Aşı
• Monovalent Aşı
• mRNA; aşı etkinliği; SARS-CoV-2

Destekleyen Kurum

uygulanamaz

Etik Beyan

Yayıncılıkta Etik Beyanı Tüm ortak yazarlar adına, gönderdiğimiz makalenin yayıncılıkta etik ilkelere uygun olduğunu beyan ederim. Başlık: COVID-19 Aşıları: Geliştirme, Etkinlik, Güvenlik ve Bağışıklık Konusunda Kapsamlı Bir İnceleme. Tüm yazarlar aşağıdakileri kabul eder: Bu makale (inceleme makalesi) tamamen orijinal çalışmaları temsil eder ve/veya başkalarının çalışmaları ve/veya sözleri kullanılmışsa, bunların uygun şekilde alıntılanmış veya kaynak gösterilmiş ve gerekli durumlarda izin alınmış olduğunu. Bu materyalin tamamı veya bir kısmı başka bir yerde yayınlanmamıştır. Makale şu anda başka bir dergide yayınlanmak üzere değerlendirilmemektedir. Yazma sürecinde üretken yapay zeka ve yapay zeka destekli teknolojiler kullanılmamıştır veya kullanılmışsa, makalede yapay zeka ve yapay zeka destekli teknolojilerin kullanımı açıklanmış ve yayınlanan çalışmada bir açıklama yer alacaktır. Üretken yapay zeka ve yapay zeka destekli teknolojiler, görüntüleri oluşturmak veya değiştirmek için kullanılmamıştır; ancak, bu tür kullanımların araştırma tasarımının bir parçası olarak özel olarak kullanılması durumunda, yöntemler bölümünde tekrarlanabilir bir şekilde açıklanmalıdır. Tüm yazarlar, makaleye yol açan önemli çalışmalara kişisel ve aktif olarak katılmışlardır ve içeriğinden ortak ve bireysel olarak sorumlu olacaklardır.

Teşekkür

Bu makale başka bir yerde yayınlanmamıştır ve herhangi bir bölümü de yayınlanmamıştır. Ayrıca başka bir dergi tarafından da değerlendirilmemektedir. Ayrıca, herhangi bir çıkar çatışması olmadığını beyan ederiz. Zaman ayırıp incelediğiniz için teşekkür ederiz. Sizden haber bekliyoruz! Saygılarımla, ________Hashi Ehsan _____________ Dr. Hashimul Ehsan (Doktora) Biyoloji Doçenti Biyoloji Bölümü, Texas A & M Üniversitesi, Victoria, 3007, N Ben Wilson, Victoria, TX, ABD E-posta: [e-mail] TEL: [361]-570-4289 FAKS: [361]-580-5507

A Comprehensive Review of COVID-19 Vaccines: Development, Efficacy, Safety, and Immunity

Öz

The coronavirus, COVID-19, pandemic has prompted an urgent global effort to develop and distribute safe and effective vaccines to mitigate the impact of the disease. This article provides a comprehensive review of COVID-19 vaccines, encompassing the current understanding of their development, efficacy, and safety based on up-to-date research findings. The review begins with an overview of the different types of COVID-19 vaccines and the process of their development and regulatory approval. It then delves into the efficacy of these vaccines, examining data from different sources, as well as factors influencing their effectiveness. Safety profiles, including common and rare adverse events, are also discussed, along with considerations for different populations. The article explores immunological responses and vaccine mechanisms, shedding light on vaccine-induced immunity and the impact of emerging variants of concern. Additionally, it addresses challenges related to vaccine distribution, coverage, and hesitancy, emphasizing the global disparities in access and strategies to address vaccine hesitancy. Finally, the article explores emerging research areas and future directions, such as the durability of immune responses, the need for booster doses, and the development of vaccines adapted to emerging variants. This comprehensive review serves to inform public health strategies, policy decisions, and future research endeavors in the ongoing battle against COVID-19.

Anahtar Kelimeler

• COVID-19 Vaccines
• COVID-19 Boosters
• Pfizer-BioNTech
• Moderna
• Bivalent Vaccine
• Monovalent Vaccine

Destekleyen Kurum

Not Applicable

Etik Beyan

Ethics in Publishing Statement I testify on behalf of all co-authors that our article submitted followed ethical principles in publishing. Title: A Comprehensive Review of COVID-19 Vaccines: Development, Efficacy, Safety, and Immunity. All authors agree that: This manuscript ( review article) represents entirely original works and or if work and/or words of others have been used, that this has been appropriately cited or quoted and permission has been obtained where necessary. This material has not been published in whole or in part elsewhere. The manuscript is not currently being considered for publication in another journal. That generative AI and AI-assisted technologies have not been utilized in the writing process or if used, disclosed in the manuscript the use of AI and AI-assisted technologies and a statement will appear in the published work. That generative AI and AI-assisted technologies have not been used to create or alter images unless specifically used as part of the research design where such use must be described in a reproducible manner in the methods section. All authors have been personally and actively involved in substantive work leading to the manuscript and will hold themselves jointly and individually responsible for its content. Corresponding author’s name: Hashimul Ehsan Date: 09/26/2025

Teşekkür

This manuscript has not been published elsewhere, nor has any part of it. It is also not under consideration by any other journal. Additionally, we declare that there are no competing interests. Thank you for your time and consideration. We look forward to hearing back from you! Sincere thanks, ________Hashi Ehsan _____________ Dr. Hashimul Ehsan (PhD) Associate Professor of Biology Department of Biology, Texas A & M University, Victoria, 3007, N Ben Wilson, Victoria, TX, USA E-mail: [e-mail] TEL: [361]-570-4289 FAX: [361]-580-5507

Kaynakça

1. Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection. 2021;49(2):199-213. doi:10.1007/s15010-020-01516-2
2. Baylor College Of Medicine. SARS-CoV-2 and COVID-19.
3. Fleming-dutra KE. COVID-19 Epidemiology and Vaccination Rates in the United States COVID-19 Cases. Published online 2022.
4. Amanda Glassman, Charles Kenny, George Yang. COVID-19 Vaccine Development and Rollout in Historical Perspective.; 2022. Accessed November 10, 2024. https://www.cgdev.org/publication/covid-19-vaccine-development-and-rollout-historical-perspective
5. Merchant A, Tania VH, Baptiste M, Ehsan H, Kaneko G. Severe acute respiratory syndrome coronavirus-2: An era of struggle and discovery leading to the emergency use authorization of treatment and prevention measures based on computational analysis. In: Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection. Elsevier; 2022:559-582. doi:10.1016/B978-0-323-91172-6.00009-1
6. Pfizer-BioNTech. A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals.; 2020.
7. Fang E, Liu X, Li M, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1). doi:10.1038/s41392-022-00950-y
8. Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021;170:83-112. doi:10.1016/j.addr.2020.12.014

9. Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release. 2015;217:345-351. doi:10.1016/j.jconrel.2015.08.007
10. Lazzaro S, Giovani C, Mangiavacchi S, et al. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology. 2015;146(2):312-326. doi:10.1111/imm.12505
11. Probst J, Weide B, Scheel B, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 2007;14(15):1175-1180. doi:10.1038/sj.gt.3302964
12. Lindsay KE, Bhosle SM, Zurla C, et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging. Nat Biomed Eng. 2019;3(5):371-380. doi:10.1038/s41551-019-0378-3
13. Liang F, Lindgren G, Lin A, et al. Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Molecular Therapy. 2017;25(12):2635-2647. doi:10.1016/j.ymthe.2017.08.006
14. Oberli MA, Reichmuth AM, Dorkin JR, et al. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. Nano Lett. 2017;17(3):1326-1335. doi:10.1021/acs.nanolett.6b03329
15. Firdessa-Fite R, Creusot RJ. Nanoparticles versus Dendritic Cells as Vehicles to Deliver mRNA Encoding Multiple Epitopes for Immunotherapy. Mol Ther Methods Clin Dev. 2020;16(March):50-62. doi:10.1016/j.omtm.2019.10.015
16. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28(2):172-176. doi:10.1038/nbt.1602
17. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. Journal of Controlled Release. 2011;151(3):220-228. doi:10.1016/j.jconrel.2010.11.004
18. Wittrup A, Ai A, Liu X, et al. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat Biotechnol. 2015;33(8):870-876. doi:10.1038/nbt.3298
19. Selby LI, Cortez‐Jugo CM, Such GK, Johnston APR. Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles. WIREs Nanomedicine and Nanobiotechnology. 2017;9(5). doi:10.1002/wnan.1452
20. Cagigi A, Loré K. Immune responses induced by mrna vaccination in mice, monkeys and humans. Vaccines (Basel). 2021;9(1):1-14. doi:10.3390/vaccines9010061
21. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today. 2019;28:100766. doi:10.1016/j.nantod.2019.100766
22. Xu S, Yang K, Li R, Zhang L. Mrna Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection. Vol 21.; 2020. doi:10.3390/ijms21186582
23. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA. Science (1979). 2004;303(5663):1529-1531. doi:10.1126/science.1093616
24. Heil F, Hemmi H, Hochrein H, et al. Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8. Science (1979). 2004;303(5663):1526-1529. doi:10.1126/science.1093620
25. Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020;26(3):311-323. doi:10.1016/j.molmed.2019.10.002
26. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. doi:10.1038/35099560
27. Hornung V, Ellegast J, Kim S, et al. 5’-Triphosphate RNA Is the Ligand for RIG-I. Science (1979). 2006;314(5801):994-997. doi:10.1126/science.1132505
28. Kato H, Takeuchi O, Mikamo-Satoh E, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. Journal of Experimental Medicine. 2008;205(7):1601-1610. doi:10.1084/jem.20080091
29. Brisse M, Ly H. Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5. Front Immunol. 2019;10(JULY):1-27. doi:10.3389/fimmu.2019.01586
30. Devoldere J, Dewitte H, De Smedt SC, Remaut K. Evading innate immunity in nonviral mRNA delivery: don’t shoot the messenger. Drug Discov Today. 2016;21(1):11-25. doi:10.1016/j.drudis.2015.07.009
31. Shimabukuro T, Oliver S. Johnson & Johnson/Janssen COVID-19 Vaccine and Cerebral Venous Sinus Thrombosis with Thrombocytopenia – Update for Clinicians on Early Detection and Treatment. In: Clinician Outreach and Communication Activity (COCA) Webinar; 2021.
32. Janssen Biotech Inc. Vaccine Technology. 2021. Accessed April 18, 2021. https://www.janssen.com/infectious-diseases-and-vaccines/vaccine-technology
33. Caiozzo VJ, Haddad F, Lee S, et al. Fact Sheet For Healthcare Providers Administering Vaccine (Vaccination Providers) Emergency Use Authorization (EUA) Of The Novavax Covid-19 Vaccine, Adjuvanted To Prevent Coronavirus Disease 2019 (Covid-19). Vol 2.; 2019.
34. Chalkias S, Harper C, Vribicky K, Walsh SR;, Essink B, Brosz A. A Bivalent Omicron-containing Booster Vaccine Against Covid-19. medRxiv. 2022;June 25:1-23. doi:10.1056/NEJMoa2208343
35. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593-602. doi:10.1038/s41586-022-04980-y
36. Chalkias S, Harper C, Vrbicky K, et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. New England Journal of Medicine. 2022;387(14):1279-1291. doi:10.1056/NEJMoa2208343
37. Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science (1979). 2022;376(6593). doi:10.1126/science.abn4947
38. Saldhi P, Simoneau CR, Ciling A, et al. Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination. Published online 2022.
39. Tang J, Novak T, Hecker J, et al. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022;13(1):1-10. doi:10.1038/s41467-022-30649-1 Pajon R, Doria-Rose NA, Shen X, et al. Corresp ondence SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. :1-4.
40. Pegu A, Connell SO, Schmidt SD, et al. HHS Public Access. 2022;373(6561):1372-1377. doi:10.1126/science.abj4176.Durability
41. Chu L, Vrbicky K, Montefiori D, et al. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial. Nat Med. 2022;28(5):1042-1049. doi:10.1038/s41591-022-01739-w Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063-1071. doi:10.1038/s41591-022-01753-y
42. Thompson MG, Natarajan K, Irving SA, et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–. MMWR Morb Mortal Wkly Rep. 2022;71(4):139-145. doi:10.15585/mmwr.mm7104e3
43. Prasad N, Derado G, Nanduri SA, et al. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(18):633-637. doi:10.15585/mmwr.mm7118a4
44. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, Aug. MMWR Recommendations and Reports. 2022;71(7):255-263. doi:10.15585/mmwr.mm7107e2
45. Centers for Disease Control and Prevention. Stay Up to Date with COVID-19 Vaccines Including Boosters. 2022. 2022. Accessed November 5, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html?s_cid=11772:covid booster schedule:sem.ga:p:RG:GM:gen:PTN.Grants:FY22
46. The United States Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose.August 31, 2022.
47. ZOE Editorial Staff. Zoe Health Study. 2022. Accessed November 5, 2022. https://health-study.joinzoe.com/blog/covid-new-top-5-covid-symptoms
48. Centers for Disease Control and Prevention. CDC COVID-19 Study Shows mRNA Vaccines Reduce Risk of Infection by 91 Percent for Fully Vaccinated People.June 7, 2021.
49. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. Published online August 9, 2022:o1939. doi:10.1136/bmj.o1939
50. Zeng B, Gao L, Zhou Q, Yu K, Sun F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022;20(1):1-15. doi:10.1186/s12916-022-02397-y
51. Buckner CM, Kardava L, Merhebi O El, et al. Recent SARS-CoV-2 infection abrogates antibody and B-cell responses to booster vaccination. medRxiv. Published online 2022. doi:https://doi.org/10.1101/2022.08.30.22279344 Centers for Disease Control and Prevention. COVID Data Tracker.; 2022.
52. Network V, June D, Link-gelles R, et al. Effectiveness of 2 , 3 , and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when. 2022;71(29):931-939.
53. Hatfield KM, Baggs J, Wolford H, et al. Effectiveness of COVID-19 vaccination against SARS-CoV-2 Infection among Residents of US Nursing Homes, Before and During the Delta variant Predominance, December 2020 – November 2021. Clinical Infectious Diseases. 2022;2019(Suppl 2):147-154. doi:10.1093/cid/ciac562
54. Link-Gelles R, Ciesla AA, Rowley EAK, et al. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023. MMWR Morb Mortal Wkly Rep. 2023;72(33):886-892. doi:10.15585/mmwr.mm7233a2
55. Dubendris H, Reses HE, Wong E, et al. Laboratory-Confirmed COVID-19 Case Incidence Rates Among Residents in Nursing Homes by Up-to-Date Vaccination Status — United States, October 10, 2022–January 8, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(4):95-99. doi:10.15585/mmwr.mm7204a3
56. Wong E, Barbre K, Wiegand RE, et al.               Effectiveness of Up-to-Date COVID-19 Vaccination in Preventing SARS-CoV-2 Infection Among Nursing Home Residents — United States, November 20, 2022–January 8, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(25):690-693. doi:10.15585/mmwr.mm7225a4
57. Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579-588. doi:10.15585/mmwr.mm7221a3
58. Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579-588. doi:10.15585/mmwr.mm7221a3
59. Centers for Disease Control and Prevention. CDC COVID Data Tracker: Vaccinations in the US. Accessed September 13, 2023. https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5
60. Oliver S, Meeting A. cdc.gov/coronavirus Evidence to Recommendations Framework: Bivalent COVID-19 Vaccine Booster Doses. Centers for Disease Control and Prevention. Published online 2022.
61. DeCuir J, Surie D, Zhu Y, et al. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period — IVY Network, 19 U.S. States, February 1, 2022–January 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(17):463-468. doi:10.15585/MMWR.MM7217A3
62. Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021;326(14):1390. doi:10.1001/jama.2021.15072
63. Hause AM, Baggs J, Marquez P, et al. COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(5152):1755-1760. doi:10.15585/mmwr.mm705152a1
64. Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094-1099. doi:10.15585/mmwr.mm7032e4
65. Fraiman J, Erviti J, Jones M, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022;40(40):5798-5805. doi:10.1016/j.vaccine.2022.08.036
66. Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. 2021;4(12):e2140364. doi:10.1001/jamanetworkopen.2021.40364 Wong HL, Tworkoski E, Ke Zhou C, et al. Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older. Vaccine. 2023;41(2):532-539. doi:10.1016/j.vaccine.2022.11.069
67. Hatfield KM, Baggs J, Wolford H, et al. Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020–November 2021. Clinical Infectious Diseases. 2022;75(Supplement_2):S147-S154. doi:10.1093/CID/CIAC562
68. Bagchi S, Mak J, Li Q, et al. Rates of COVID-19 Among Residents and Staff Members in Nursing Homes — United States, May 25–November 22, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):52-55. doi:10.15585/MMWR.MM7002E2 Centers for Disease Control and Prevention. How to Protect Yourself and Others | CDC. Accessed October 14, 2023. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html
69. Prasad N, Derado G, Nanduri SA, et al. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant — United States, February 14–March 27, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(18):633-637. doi:10.15585/MMWR.MM7118A4
70. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-651. doi:10.1001/JAMA.2022.0470
71. Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA. 2022;327(22):2210-2219. doi:10.1001/JAMA.2022.7493
72. Fleming-Dutra KE, Ciesla AA, Roper LE, et al. Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023. MMWR Morb Mortal Wkly Rep. 2023;72(7):177-182. doi:10.15585/MMWR.MM7207A3
73. outbreak.info SARS-CoV-2 data explorer. Accessed September 22, 2023. https://outbreak.info/
74. Rosenblum HG, Wallace M, Godfrey M, et al. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022;71(45):1436-1441. doi:10.15585/MMWR.MM7145A2
75. Link-Gelles R, Ciesla AA, Roper LE, et al. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 2023. MMWR Morb Mortal Wkly Rep. 2023;72(5):119-124. doi:10.15585/MMWR.MM7205E1
76. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. 2022;327(7):639-651. doi:10.1001/JAMA.2022.0470
77. Accorsi EK, Britton A, Shang N, et al. Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron. New England Journal of Medicine. 2022;386(25):2433-2435. doi:10.1056/NEJMC2203165/SUPPL_FILE/NEJMC2203165_DISCLOSURES.PDF
78. Increasing Community Access to Testing (ICATT) for COVID-19. Accessed September 23, 2023. https://www.cdc.gov/icatt/index.html
79. Dingermann T. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):44. doi:10.15585/MMWR.MM7148E1
80. National Center for Immunization and Respiratory Diseases. Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. Accessed October 11, 2023. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#vaccination-people-immunocompromised
81. Natarajan K, Prasad N, Dascomb K, et al. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):495-502. doi:10.15585/MMWR.MM7113E2
82. Link-Gelles R, Levy ME, Natarajan K, et al. Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods. medRxiv. Published online October 5, 2022:2022.10.04.22280459. doi:10.1101/2022.10.04.22280459
83. Tenforde MW, Weber ZA, Natarajan ; Karthik, et al. Supplementary document showing detailed changes to the corrected and republished report: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022. 2023;72. Accessed September 22, 2023. https://stacks.cdc.gov/view/cdc/125679
84. Surie D, Bonnell L, Adams K, et al. Morbidity and Mortality Weekly Report Effectiveness of Monovalent MRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States-IVY Network, 18 States. Vol 71.; 2022.
85. Surie D, DeCuir J, Zhu Y, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(5152):1625-1630. doi:10.15585/MMWR.MM715152E2
86. Surie D, Bonnell L, Adams K, et al. Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1327-1334. doi:10.15585/MMWR.MM7142A3
87. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(29):931-939. doi:10.15585/MMWR.MM7129E1
88. Britton A, Embi PJ, Levy ME, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1335-1342. doi:10.15585/MMWR.MM7142A4
89. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022. MMWR Morb Mortal Wkly Rep. 2022;71(29):931-939. doi:10.15585/MMWR.MM7129E1
90. Tenforde MW, Self WH, Gaglani M, et al. Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):459-465. doi:10.15585/MMWR.MM7112E1
91. Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lancet. 2022;399(10328):924-944. doi:10.1016/S0140-6736(22)00152-0
92. Link-Gelles R, Weber ZA, Reese SE, et al. Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023. MMWR Morb Mortal Wkly Rep. 2023;72(21):579-588. doi:10.15585/mmwr.mm7221a3
93. Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. JAMA. 2022;327(22):2210. doi:10.1001/jama.2022.7493
94. Britton A, Embi PJ, Levy ME, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION
95. Network, 10 States, December 2021—August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(42):1335-1342. doi:10.15585/mmwr.mm7142a4
96. Price AM, Olson SM, Newhams MM, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. New England Journal of Medicine. 2022;386(20):1899-1909. doi:10.1056/nejmoa2202826
97. Halasa NB, Olson SM, Staat MA, et al. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants. New England Journal of Medicine. 2022;387(2):109-119. doi:10.1056/nejmoa2204399
98. Fowlkes AL, Yoon SK, Lutrick K, et al. Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022. MMWR Morb Mortal Wkly Rep. 2022;71(11):422-428. doi:10.15585/mmwr.mm7111e1
99. Center for Disease Control and Prevention. Vaccines for Moderately to Severely Immunocompromised People. August 30, 2024.
100. Center for Disease Control and Prevention. CDC Recommends Second Dose of 2024-2025 COVID-19 Vaccine for People 65 Years and Older and for People Who are Moderately or Severely Immunocompromised. October 23, 2024. Accessed November 10, 2024.
101. U.S. Food and Drug Administration. FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants.https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently. August 22, 2024. Accessed November 11, 2024.
102. Mateo-Urdiales A, Sacco C, Fotakis EA, et al. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study. Lancet Infect Dis. 2023;23(12):1349-1359. doi:10.1016/S1473-3099(23)00374-2
103. Jones JM, Manrique IM, Stone MS, et al. Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status — United States, April 2021–September 2022. MMWR Morb Mortal Wkly Rep. 2023;72(22):601-605. doi:10.15585/mmwr.mm7222a3
104. World Health Organization. Coronavirus disease (COVID-19). August 9, 2023. Accessed November 11, 2024. https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19)
105. Hudson A, Montelpare WJ. Predictors of Vaccine Hesitancy: Implications for COVID-19 Public Health Messaging. Int J Environ Res Public Health. 2021;18(15):8054. doi:10.3390/ijerph18158054
106. Klein NP, Stockwell MS, Demarco M, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in
107. Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network. MMWR Morb Mortal Wkly Rep. 2022;71(9):352-358. doi:10.15585/mmwr.mm7109e3